Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1157601.RAZhHg_yTagti1f6c87dHmTC2GXPMTYNpyZj_s5_26VSk130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1157601.RAZhHg_yTagti1f6c87dHmTC2GXPMTYNpyZj_s5_26VSk130_assertion type Assertion NP1157601.RAZhHg_yTagti1f6c87dHmTC2GXPMTYNpyZj_s5_26VSk130_head.
- NP1157601.RAZhHg_yTagti1f6c87dHmTC2GXPMTYNpyZj_s5_26VSk130_assertion description "[Here, we demonstrate that for one patient, with the first reported fibroblast growth factor receptor 2 (FGFR2) fusion transcript in ovarian cancer, circulating tumor DNA (ctDNA) is a more sensitive and specific biomarker than CA125, and it can also inform on a candidate therapeutic.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1157601.RAZhHg_yTagti1f6c87dHmTC2GXPMTYNpyZj_s5_26VSk130_provenance.
- NP1157601.RAZhHg_yTagti1f6c87dHmTC2GXPMTYNpyZj_s5_26VSk130_assertion evidence source_evidence_literature NP1157601.RAZhHg_yTagti1f6c87dHmTC2GXPMTYNpyZj_s5_26VSk130_provenance.
- NP1157601.RAZhHg_yTagti1f6c87dHmTC2GXPMTYNpyZj_s5_26VSk130_assertion SIO_000772 24563622 NP1157601.RAZhHg_yTagti1f6c87dHmTC2GXPMTYNpyZj_s5_26VSk130_provenance.
- NP1157601.RAZhHg_yTagti1f6c87dHmTC2GXPMTYNpyZj_s5_26VSk130_assertion wasDerivedFrom befree-2016 NP1157601.RAZhHg_yTagti1f6c87dHmTC2GXPMTYNpyZj_s5_26VSk130_provenance.
- NP1157601.RAZhHg_yTagti1f6c87dHmTC2GXPMTYNpyZj_s5_26VSk130_assertion wasGeneratedBy ECO_0000203 NP1157601.RAZhHg_yTagti1f6c87dHmTC2GXPMTYNpyZj_s5_26VSk130_provenance.